Eric Cohen - Mauna Kea Insider

MKEA -- France Stock  

EUR 3.18  0.24  8.16%

Mr. Eric Cohen serves as Vice President of Finance at Mauna Kea Technologies SA. Prior to joining the Company, he served as Chief Financial Officer of Biocortech and as Deputy General Manager and Chief Financial Officer of publiclyheld Hybrigenics. Prior to joining Hybrigenics, he was Finance Director of Teva Pharmaceutical in France. He was also previously Chief Financial Officer of Radio BFM
33 1 48 24 03 45
Cohen holds an MBA from University of London and a Masters in Finance from Dauphine University in Paris.

Eric Cohen Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (25.43) % which means that it has lost $25.43 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (73.44) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 6.95 M in total debt with debt to equity ratio (D/E) of 41.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mauna Kea Technologies SA has Current Ratio of 5.67 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 4 records

CFO Since

Jerome DestoppeleirSuperSonic Imagine SA
Bernard ReymannMedian Technologies SA
Didier LenormandCellnovo Limited
Anne RenevotEOS imaging SA

Entity Summary

Mauna Kea Technologies SA, a medical device company, develops and sells endomicroscopy and optical biopsy for the diagnosis and treatment of cancer and other diseases. The company was founded in 2000 and is headquartered in Paris, France. Mauna Kea operates under Medical Devices classification in France and traded on Paris Stock Exchange. It employs 90 people.Mauna Kea Technologies SA (MKEA) is traded on Paris Stock Exchange in France. It is located in 9, rue d'Enghien and employs 90 people.

Mauna Kea Technologies Leadership Team

Olivier Regnard, Deputy CEO, CFO
Bertrand Talhouet, Representative of Creadev on the Board of Directors
Eric Cohen, CFO and VP of Fin.
Gilles Brisson, Chairman, Independent Director
Alexandre Loiseau, CEO, Director
Guillaume Bailliard, President for North America
Christopher McFadden, Director
Francois Lacombe, Chief Scientific Officer
Christopher Tihansky, Chief Devel. Officer and President of North America
JeanLuc Boulnois, Director
Bruno Villaret, Vice President of International Sales
Joseph DeVivo, Non-Executive Independent Director
Christophe Bailleul, Vice-President Clinical Affairs, Health Economics and Market Access
Agnes Rouffiac, Director of Human Resources
Veronique Dentan, Director of Operations
Sebastien Cadet, Global Director of Marketing and OEM Leader
Sacha Loiseau, Founder, CEO and Director
Molly ONeill, Director
Pierre Forest, COO
John Soto, COO
Marie Meynadier, Director

Stock Performance Indicators

Did you try this?

Run Pair Correlation Now


Pair Correlation

Compare performance and examine historical correlation between any two equity instruments
All  Next Launch Pair Correlation

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Portfolio Quick Import module to import or update all your transactions via one easy-to-use interface.